Pharmaceuticals, Biotechnology & Life Sciences

Alnylam’s new partnerships with Tenaya Therapeutics and Helix boost its RNAi portfolio, driving precision cardiology and data‑powered target discovery for future growth.

Incyte’s European approval of Zynyz offers a new immunotherapy option for rare SCAC patients, highlighting cost‑effectiveness, operational challenges, and market prospects.

Lonza’s sale of its Capsules & Health Ingredients division fuels a shift to high‑margin, tech‑driven contract manufacturing—boosting ROI, reducing costs, and enhancing pharma quality.

Discover why Hikma Pharmaceuticals PLC is a stable, diversified choice for investors seeking steady earnings, global reach, and balanced risk in the pharma sector.

Merck KGaA’s mixed signals: asset culling, 2026 profit warning, and a strategic pivot to China—why analysts upgrade despite market volatility.

Novo Nordisk partners with Hims & Hers to deliver obesity drugs via digital health, boosting patient access, safety data, and cost‑effective care.

Argenx SE to reveal new clinical data on efgartigimod for myasthenia gravis and CIDP at the 2026 AAN meeting—showcasing its antibody‑blockade platform’s potential to reshape the $3.2 bn autoimmune neurology market and impact investor outlook.

Roche’s market dip amid geopolitical tension masks strong clinical progress—phase‑III ALLEGORY shows 46% SLE remission, while phase‑II Petrelintide cuts BMI by 2.8 kg/m².

Insmed’s valuation rises as Bank of America lifts its price target to $211, backed by strong PAH trial results and a 85‑hire talent boost, signaling growth potential in rare‑disease therapeutics.

Thermo Fisher Scientific drives DNA microarray growth with advanced platforms, supporting investors, clinicians, and health systems through high‑throughput diagnostics and regulatory‑compliant solutions.